China Pharma Holdings (CPHI) Cost of Revenue (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Cost of Revenue came in at $698049.0 in Q1 2026, down 45.14% YoY from $1.3 million in Q1 2025, and down 82.59% on a QoQ basis from $4.0 million in Q4 2025.
China Pharma Holdings (CPHI) Cost of Revenue (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Cost of Revenue data on file, last reported at $698049.0 in Q1 2026.
- Quarterly Cost of Revenue fell 45.14% year-over-year to $698049.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 188.67% YoY) and the FY2025 annual result came in at $4.3 million, up 708.63% from the prior year.
- Cost of Revenue declined to $698049.0 in Q1 2026, from $4.0 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $4.0 million in Q4 2025 to a low of $78041.0 in Q3 2025.
- A 5-year average of $1.0 million and a median of $266451.0 in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue tumbled 93.39% — and 2025, when it surged 2196.82%.
- Tracing CPHI's Cost of Revenue over 5 years: stood at $2.9 million in 2022, then sank by 90.98% to $259552.0 in 2023, then plunged by 32.74% to $174579.0 in 2024, then surged by 2196.82% to $4.0 million in 2025, then sank by 82.59% to $698049.0 in 2026.
- The last three Cost of Revenue figures came in at $698049.0 (Q1 2026), $4.0 million (Q4 2025), and $78041.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | China Pharma Holdings | 41.34 Mn | 41.03 Mn | 83,566.00 | 864,774.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 698,049.00 |
| Mar 31, 2026 | 698,049.00 |
| Dec 31, 2025 | 4.01 Mn |
| Dec 31, 2025 | 4.01 Mn |
| Sep 30, 2025 | 78,041.00 |
| Sep 30, 2025 | 78,041.00 |
| Jun 30, 2025 | 101,292.00 |
| Jun 30, 2025 | 101,292.00 |
| Mar 31, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 174,579.00 |
| Dec 31, 2024 | 174,579.00 |
| Sep 30, 2024 | 134,603.00 |
| Sep 30, 2024 | 134,603.00 |
| Jun 30, 2024 | 111,455.00 |
| Jun 30, 2024 | 111,455.00 |
| Mar 31, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Dec 31, 2023 | 259,552.00 |
| Dec 31, 2023 | 259,552.00 |